As of November 6, 2026, Voyager Therapeutics, Inc. is a publicly traded company (Nasdaq: VYGR); its largest reported holder is Millennium, with 7.4% on Schedule 13G/A of July 31, 2026, then Armistice Capital (5.58%). The largest insider holding is Alfred Sandrock, the chief executive and president, with 472,549 shares (0.76% of shares outstanding), per Form 4 of April 3, 2026 (Schedule 13G/A, July 31, 2026).
Is this your company?
About to sign with, pay or invest in Voyager Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Voyager Therapeutics, Inc. a real, registered company?
- Voyager Therapeutics, Inc. files with the SEC under CIK 1640266 (its SEC filings).
- Its shares are listed under the ticker VYGR on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Lexington, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Voyager Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Robin Swartz, President (Form 8-K filed 2026-10-21). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Armistice Capital (filed 2026-08-14).
Who are Voyager Therapeutics, Inc.'s owners and officers?
Voyager Therapeutics, Inc.: incorporated in Delaware; business address in Lexington, Massachusetts; industry Biological Products, (No Diagnostic Substances) (Form D, 2026-10-21).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-01-17)
- : Executive Officer (Form D, 2024-01-17)
- : Executive Officer (Form D, 2024-01-17)
- : Executive Officer (Form D, 2024-01-17)
- : Executive Officer (Form D, 2024-01-17)
- : Director (Form D, 2024-01-17)
- : Director (Form D, 2024-01-17)
- : Director (Form D, 2024-01-17)
- : Director (Form D, 2024-01-17)
- : Director (Form D, 2024-01-17)
- : Director (Form D, 2024-01-17)
- : Director (Form D, 2024-01-17)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Armistice Capital, LLC | 5.58% |
| Schedule 13G/A, 2026-07-31 | Millennium Management LLC | 7.4% |
| Schedule 13G/A, 2026-05-15 | Armistice Capital, LLC | 5.87% |
| Schedule 13G/A, 2026-05-15 | Ecor1 Capital, LLC | 0% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-18 | Armistice Capital, LLC | 7.19% |
| Schedule 13G/A, 2026-02-17 | Ecor1 Capital, LLC | 6.8% |
| Schedule 13G, 2026-01-26 | Millennium Management LLC | 6.1% |
| Schedule 13G/A, 2025-11-14 | Ecor1 Capital, LLC | 6.8% |
| Schedule 13G/A, 2025-11-14 | Armistice Capital, LLC | 7.57% |
| Schedule 13G/A, 2025-08-14 | Armistice Capital, LLC | 8.65% |
Questions about who owns Voyager Therapeutics, Inc.
Who owns Voyager Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Voyager Therapeutics, Inc.: Millennium Management LLC (7.4%, Schedule 13G/A, filed 2026-07-31) and Armistice Capital, LLC (5.58%, Schedule 13G/A, filed 2026-08-14).
Who are the largest shareholders of Voyager Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Voyager Therapeutics, Inc. on this page are Millennium Management LLC (7.4%) and Armistice Capital, LLC (5.58%).
When did Millennium Management LLC buy into Voyager Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Millennium Management LLC on this page is the Schedule 13G, filed 2026-01-26, reporting 6.1%; its latest, Schedule 13G/A filed 2026-07-31, reports 7.4%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Voyager Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Voyager Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Voyager Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
21 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-21 | Robin Swartz | President | appointed | |
| Form 8-K, 2026-04-21 | Robin Swartz | Director | appointed |
Which insiders own Voyager Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 472,549 shares (0.76% of shares outstanding) (Form 4, 2026-04-03).
- , the president: 267,988 shares (0.43% of shares outstanding) (Form 4, 2026-11-03).
- , the chief medical officer: 183,914 shares (0.30% of shares outstanding) (Form 4, 2026-02-10).
- , the chief scientific officer: 178,718 shares (0.29% of shares outstanding) (Form 4, 2026-11-03).
- , the chief financial officer: 151,416 shares (0.24% of shares outstanding) (Form 4, 2026-02-26).
Shares outstanding: 62,229,182 as of 2026-10-30, from the company's latest SEC cover page.
How much has Voyager Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-01-17 | $20M | $20M |
| Form D, 2023-03-03 | $39.03M | $39.03M |
Keep reading
More on Voyager Therapeutics, Inc. and the records around it.
Voyager Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Leadership changes Apr 2026
Companies that share a holder
- EcoR1 Capital, LLC also filed stake reports on 20 other companies: Mereo BioPharma Group plc (Aug 2026), Alto Neuroscience, Inc. (Jul 2026), Fulcrum Therapeutics, Inc. (Jun 2026)
- Integrated Core Strategies (US) LLC also filed stake reports on 63 other companies: SkinHealth Systems Inc. (Nov 2026), Infinite Eagle Acquisition Corp. (Nov 2026), Longeveron Inc. (Nov 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/voyager-therapeutics